Three names dominate the GLP conversation: semaglutide, tirzepatide, and retatrutide. They belong to the same broad class but differ in a crucial way — the number of receptor pathways each one activates.
The one-line difference
- Semaglutide — single agonist (GLP-1). The original blockbuster mechanism.
- Tirzepatide — dual agonist (GLP-1 + GIP).
- Retatrutide — triple agonist (GLP-1 + GIP + glucagon).
What the research suggests
Across published trials, the general pattern researchers report is that broader receptor coverage has correlated with larger metabolic effects in study populations. Semaglutide established the category; tirzepatide’s dual mechanism reported stronger results; retatrutide’s Phase 2 data reported the largest body-weight reductions of the three at its highest studied doses. These are research findings in controlled settings, not guarantees of individual outcome.
Take our 60-second quiz for a personalized recommendation and unlock 35% off your first order of USA-made, COA-verified GLP.
Practical research considerations
All three are peptides that degrade if handled poorly, so purity and cold-chain handling matter regardless of which you study. Learn why third-party COAs matter and how we verify every batch. New to the category? Start with what retatrutide is.
For research and educational use only. The information here is not medical advice and RDAmd products are not intended to diagnose, treat, cure, or prevent any disease or for human consumption. Retatrutide is an investigational compound and is not approved by the FDA. Always consult a qualified professional.
